Publications — Radcliffe Department of Medicine

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Carbonic anhydrase 9 (CA9) expression in non-small-cell lung cancer: correlation with regulatory FOXP3+T-cell tumour stroma infiltration.

Giatromanolaki A. et al, (2020), Br J Cancer

CRISPR/Cas9-Mediated Foxp1 Silencing Restores Immune Surveillance in an Immunocompetent A20 Lymphoma Model.

Felce SL. et al, (2020), Front Oncol, 10

ADGRL4/ELTD1 Silencing in Endothelial Cells Induces ACLY and SLC25A1 and Alters the Cellular Metabolic Profile.

Favara DM. et al, (2019), Metabolites, 9

Development of therapeutic anti-JAGGED1 antibodies for cancer therapy.

Masiero M. et al, (2019), Mol Cancer Ther

ADGRL4/ELTD1 is a highly conserved angiogenesis-associated orphan adhesion GPCR that emerged with the first vertebrates and comprises 3 evolutionary variants.

Favara DM. et al, (2019), BMC Evol Biol, 19

FOXP3 infiltrating lymphocyte density and PD-L1 expression in operable non-small cell lung carcinoma.

Giatromanolaki A. et al, (2019), Exp Lung Res, 1 - 8

The oncogenic roles of TRPM ion channels in cancer

Wong KK. et al, (2019), Journal of Cellular Physiology

Identification of survivin as a promising target for the immunotherapy of adult B-cell acute lymphoblastic leukemia.

Boullosa LF. et al, (2018), Oncotarget, 9, 3853 - 3866

DNMT1 is predictive of survival and associated with Ki-67 expression in R-CHOP-treated diffuse large B-cell lymphomas.

Loo SK. et al, (2017), Pathology, 49, 731 - 739

ELTD1/ADGRL4, a novel adhesion GPCR regulator of tumour angiogenesis, suppresses lipid metabolism in endothelial cells, and is upregulated in breast cancer endothelium and epithelium

Favara DM. et al, (2017)

TRPM4 expression is associated with activated B cell subtype and poor survival in diffuse large B cell lymphoma.

Loo SK. et al, (2017), Histopathology, 71, 98 - 111

Development of a T-cell Receptor Mimic Antibody against Wild-Type p53 for Cancer Immunotherapy.

Li D. et al, (2017), Cancer Res, 77, 2699 - 2711

The significance of FOXP1 in diffuse large B-cell lymphoma.

Gascoyne DM. and Banham AH., (2017), Leuk Lymphoma, 58, 1037 - 1051

Anti p53/HLA-A*0201 T-cell Receptor Mimic Antibody

BANHAM A. and Li D., (2017)

Vitamin D Receptor Expression in Plasmablastic Lymphoma and Myeloma Cells Confers Susceptibility to Vitamin D.

Gascoyne DM. et al, (2017), Endocrinology, 158, 503 - 515

Engineering chimeric human and mouse major histocompatibility complex (MHC) class I tetramers for the production of T-cell receptor (TCR) mimic antibodies.

Li D. et al, (2017), PLoS One, 12

Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse Large B Cell Lymphoma Patients.

Ait-Tahar K. et al, (2017), Adv Hematol, 2017

Therapeutic Antibodies against Intracellular Tumor Antigens.

Trenevska I. et al, (2017), Front Immunol, 8

FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures.

Wong KK. et al, (2016), Oncotarget, 7, 52940 - 52956

N-terminally truncated FOXP1 protein expression and alternate internal FOXP1 promoter usage in normal and malignant B cells.

Brown PJ. et al, (2016), Haematologica, 101, 861 - 871

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?